



www.elsevier.com/locate/ejphar

Notice to Authors

1. General

1.1. Manuscripts

For submission the original and 3 copies, written in English, complete with 4 sets of figures and tables should be sent to:

The Editorial Office, European Journal of Pharmacology, Universiteitsweg 100, 3584 CG Utrecht, The Netherlands (Tel.: (31-30) 253-8833, Fax: (31-30) 253-9033). The final version of the manuscript should be sent to the Editorial Office on disk (see section 1.3) together with the original and a copy of a printout of the revised manuscript. Manuscripts submitted by fax transmission will not be considered.

Manuscripts submitted to the journal are accepted on the understanding that: (1) they are subject to editorial review and (2) the recommendations of the Declarations of Helsinki and Tokyo, for humans, and the European Community guidelines for the use of experimental animals have been adhered to. Authors must state in the manuscript that the protocol complies with these guidelines and were approved by their institutional ethics committee. The submitted manuscript should be accompanied by a written statement that the manuscript has not and will not be published in whole or in part in any other journal. This statement should have the signature of all authors.

1.2. Typing

Manuscripts should be typewritten or printed with double spacing (at least 6 mm between lines) and with wide margins (not more than 26 lines per page). The possibility that accepted manuscripts will be electronically scanned makes it essential that the typing/printing be of the highest quality. A laser-type or similar quality printer or a high-quality typewriter with a black carbon ribbon should be used to ensure proper contrast for the original. A standard, at least 12-point (0.0138 inch), typeface, not distorted and neither reduced nor enlarged, is to be used. Manuscripts printed with low-quality printers will be returned for retyping with an acceptable typeface.

Authors not fully acquainted with proper English usage should have their manuscripts read by a colleague proficient in English before submission of the manuscript. On their acceptance, manuscripts will, if necessary, be revised for English style and language. Should the changes be extensive, the manuscripts will be returned to the authors for retyping.

Authors in Japan please note: Upon request Elsevier Science Japan will provide authors with a list of people who can check and improve the English of their manuscript (before submission). Please contact the Tokyo office: Elsevier Science K.K. 1-9-15 Higashi-Azabu, Minatoku, Tokyo 106-0044; Tel. (03) 5561 5032; Fax (03) 55615045.

Webster's New International Dictionary or the Oxford English Dictionary should be consulted for spelling. Latin plurals should not be used if the English equivalent has become the accepted form, e.g., formulas not formulae. Use of hyphens, capital letters, numbers written or spelled out (e.g., 8 or eight) should be consistent throughout the manuscript. Words at the end of a line should not be hyphenated.

1.3. Electronic manuscripts

The preferred storage medium is a $5\frac{1}{4}$ or $3\frac{1}{2}$ inch disk in MS-DOS format, although other systems are welcome, e.g., NEC and Macintosh (in this case, save your file in the usual manner, do not use the option 'save in MS-DOS format'). If your word processor features the option to save files 'in flat ASCII', please do not use it. Format your disk correctly and ensure that only the relevant file (one complete article only) is on the disk. Also, specify the type of computer and word processing package used and label the disk with your name and the name of the file on the disk. Please do not split the article into separate files (title page as one file, text as another, etc.). Ensure that the letter '1' and digit '1' (also letter 'O' and digit '0') have been used properly, and structure your article (tabs, indents, etc.) consistently. Characters not available on your word processor (Greek letters, mathematical symbols, etc.) should not be left open but indicated by a unique code (e.g., gralpha, @, #, etc., for the Greek letter α). Such codes should be used consistently throughout the entire text. Please make a list of such codes and provide a key. Do not allow your word processor to split words and do not use a 'justified' layout. Please adhere strictly to the general instructions on style/arrangement and, in particular, the reference style of

vi Notice to Authors

the journal. It is very important that you save your file in the word processor format. At acceptance your disk plus one printed and exactly matching version will be forwarded to the publishers, from whom further information may be obtained.

1.4. Abbreviations

Abbreviations are a hindrance for the reader. Use as few abbreviations as possible and write out names of compounds, receptors, etc., in full throughout the text of the manuscript, with the exceptions given below.

<u>Unnecessary abbreviations</u>. Unnecessary abbreviations such as AP, TEP, TFT, CER, nAc and LTFSE (for afterpotential, transepithelial potential, tail-flick test, cold-exposed rats, nucleus accumbens and sympatho-excitatory lateral tegmental field) are not acceptable.

Receptor abbreviations. Receptor abbreviations such as $\beta\,AR,\,mAChR,\,BZR$ for β -adrenoceptor, muscarinic receptor, benzodiazepine receptor, respectively, should not be used. For receptors avoid the abbreviation "R". With receptor subtypes mention the full receptor name throughout the manuscript: e.g. adenosine A_1 receptor, dopamine D2 receptor, melanocortin MC_3 receptor, endothelin ET_A receptor.

Generic names. Generic names should not be abbreviated. For example, AMP, HAL, HIST, RAMH, TAM, SST, for amphetamine, haloperidol, histamine, (R)- α -methylhistamine, tamoxifen, somatostatine, are not accepted. Abbreviations which had been accepted so far should no longer be used (e.g. NA, DA, ACh, ET, LTs, IL, TX, PG for noradrenaline, dopamine, acetylcholine, endothelin, leukotrienes, interleukin, thromboxane, prostaglandin).

Abbreviations which have come to replace the full term. Abbreviations which have come to replace the full term (GABA, DOPA, EDRF, 5-HT, for γ -aminobutyric acid, 3,4-dihydroxyphenylalanine, endothelium-derived relaxing factor, 5-hydroxytryptamine) may be used, provided the term is spelled out in the abstract and in the body of the manuscript the first time the abbreviation is used.

Unwieldy chemical names may be abbreviated. For example, 8-OH-DPAT, DOI, DTG, BAPTA for 8-hydroxy-2-(di-n-propylamino)tetralin, 1-(2,5-dimethoxy-4-iodophenyl)—aminopropane, 1,3-di(2-tolyl)-guanidine, 1,2-bis(o-aminophenoxy)ethane-N, N', N'-tetraacetic acid, are acceptable; however, the full chemical name should be given once in the abstract and in the body of the manuscript, followed in both cases by the abbreviation.

<u>Code names</u>. Code names may be used, but the full chemical name should be given in the abstract and in the text

Authors not conforming to these demands will have their manuscript returned for correction, with delayed publication as the result.

Some abbreviations may be used without definition:

ADP, CDP GDP, IDP, UDP AMP etc. ADP etc. ATP etc.	5'-pyrophosphates of adenosine, cytidine, guanosine, inosine, uridine adenosine 5'-monophosphate etc. adenosine 5'-diphosphate etc.
CM-cellulose	adenosine 5'-triphosphate etc. carboxymethylcellulose
CoA and	coenzyme A and its acyl derivatives
acetyl-CoA	coenzyme A and its acyl derivatives
DEAE-	O-(diethylaminoethyl)-cellulose
cellulose	
DNA	deoxyribonucleic acid
EGTA	ethylene glycol-bis(β-aminoethyl
	ether) N, N, N', N' -tetraacetic acid
FAD	flavin-adenine dinucleotide
FMN	flavin mononucleotide
GSH, GSSG	glutathione, reduced and oxidized
HEPES	4-(2-hydroxyethyl)-1-piperazine- ethanesulphonic acid
NAD	nicotinamide-adenine dinucleotide
NADP	nicotinamide-adenine dinucleotide phosphate
NMN	nicotinamide mononucleotide
P_i, PP_i	orthophosphate, pyrophosphate
RNA	ribonucleic acid
Tris	2-amino-2-hydroxymethylpropane- 1,3-diol
	1,5-0101

Two alternative conventions are currently in use in some cases. For example, for the phosphoinositides there are both the abbreviations recommended by the IUPAC-IUB and those of the Chilton Convention (e.g., $PtdIns(4,5)P_2$ vs. PIP_2 for phosphatidylinositol 4,5-biphosphate). The journal will accept either of these forms but not their combination.

Abbreviations of units of measurements and other terms are as follows:

kg
g
mg
μg
mol
mmol
μmol
nmol
pmol
fmol
eq
h
min
S

Notice to Authors vii

millisecond	ms
microsecond	μs
merosecond	μο
Units of volume	
litre	1
millilitre	ml
microlitre	μl
Units of length	
metre	m
centimetre	cm
millimetre	mm
micrometre	
	μm
nanometre	nm
Units of concentration	
molar (mol/l)	M
millimolar	mM
micromolar	μM
nanomolar	nM
picomolar	pM
	r
Units of heat, energy, electricity	
joule	J
degree Celsius (centigrade)	°C
coulomb	C
	A
ampere	
volt	V
ohm	Ω
siemens	S
Units of radiation	
curie	Ci
counts per minute	cpm
disintegrations per minute	dpm
becquerel	Bq
becquerer	ьq
Miscellaneous	
gravity	g
dissociation constant	
	$K_{\rm d}$
median doses	LD_{50} , ED_{50}
probability	P
routes of drug administration	i.v., i.p., s.c.,
	i.m., i.c., i.t.,
	i.c.v., i.v.t., p.o.
square centimetre	cm ²
standard deviation	S.D.
standard error of the mean	S.E.M.
Svedberg unit of sedimentation	S
	3
coefficient	S
coefficient Hill coefficient	$n_{ m H}$

The isotope mass number should appear before the atomic symbol, e.g., [³H]noradrenaline, [¹⁴C]choline. Ions should be written: Fe³⁺, Ca²⁺, Mg²⁺. The term absorbance (A) is preferred to extinction or optical density. For abbreviations not included in this list consult: *Units, Symbols and Abbreviations, A Guide for Biological and Medical Authors and Editors*, 1994 (The Royal Society of

Medicine, London), ISBN 0-905958-78-0, or *Scientific Style and Format. The CBE Manual for Authors, Editors, and Publishers*, 6th edn. (Cambridge University Press, Cambridge), ISBN 0-521-47154-0.

1.5. Nomenclature

Only generic and chemical names of drugs should be used, although a proprietary equivalent may be indicated once, in parentheses. *Pharmacological and Chemical Synonyms*, E.E.J. Marler, 9th edn. (Elsevier, Amsterdam, 1995) may be consulted.

The nomenclature of chemical substances should be consistent, clear and unambiguous, and should conform to the usage of the American Chemical Society and the convention recommended by the International Union of Pure and Applied Chemistry (IUPAC). When in doubt, writers should consult the indexes of *Chemical Abstracts*; the various reports and pamphlets of the American Chemical Society Committee on Nomenclature, Spelling and Pronunciation; *Biochemical Nomenclature and Related Documents* from the International Union of Biochemistry and Molecular Biology (IUBMB) (Portland Press, London).

When drugs which are mixtures of stereoisomers are used, the fact that they have a composite nature and the implication of this for interpretation of the data and drawing of conclusions should be made clear. The use of the appropriate prefix is essential. Use of the generic name alone without a prefix would be taken to refer to agents with no stereoisomers. The nomenclature of the various isomers and isomeric mixtures can be found in: (i) *IUPAC*, *Nomenclature of Organic Chemistry*, eds. J. Rigaudy and S.P. Klesney (Pergamon Press, London), 1979, p. 481; (ii) *Signs of the time: the need for a stereochemically informative generic name system*, Simonyi, M., J. Gal and B. Testa, 1989, *Trends Pharmacol. Sci.* 10, 349. For nomenclature of peptides, see *Neuropeptides*, Vol. 1, 1981, p. 231.

The nomenclature of receptors and their subtypes, of ion channels and of transporters should conform to the *TiPS 2001 Nomenclature Supplement*. Copies of this supplement are available from the publisher (Current Trends, 84 Theobald's Road, London, WC1X 8RR, UK. Tel.: +44 20 7611 4400; Fax: +44 20 7611 4470).

The trivial name of enzymes may be used in the text, but the systematic name and classification number according to *Enzyme Nomenclature*, rev. edn. (Academic Press, New York, NY, 1984) should be quoted the first time an enzyme is mentioned.

1.6. Editorial review

Rapid communications are assessed for acceptability by the editors of the journal, usually advised by a member of the editorial board or by one of the consultants. Full-length manuscripts, short communications and reviews are gener-

viii Notice to Authors

ally submitted to 2 referees who are chosen for their ability to evaluate the work. Authors may request that certain referees not be chosen. Members of the editorial board will usually be called upon for advice when there is disagreement among the referees or between referees and authors, or when the editors believe that the manuscript has not received adequate consideration by the referees.

In order to reduce mailing costs, manuscripts will not be returned. Only the decision of the editorial office, together with the advice of the referees will be sent to the author(s). Referees will be requested to keep the copy of the manuscript which they have received for evaluation until they have been notified of the final decision concerning the manuscript. They should then destroy it.

All referees' comments must be responded to, and suggested changes be made. The author should detail the changes made in response to the referees' comments and suggestions in an accompanying letter. If the author disagrees with some suggested changes, the reason, supported by data, should be given. The editors may refuse to publish manuscripts from authors who persistently ignore referees' comments. Revised manuscripts should be returned in duplicate to the editors. Handwritten additions or corrections will not be accepted. Only complete retyping of the pages affected by revision is acceptable. A revised manuscript should be received by the editorial office not later than 5 weeks (in the case of minor revision) or 10 weeks (in the case of extensive revision) after the editorial decision was sent to the author(s); otherwise it will be processed as a new manuscript.

2. Organization and style of manuscripts

Authors should consult a current issue of the journal for the general manner of presentation. Manuscripts should be written in clear, concise English, bearing in mind that English is not the native language of many of the readers. Terms that are not generally understood and insiders' jargon should be avoided.

For general aid in the preparation of manuscripts, author(s) may find the following guides useful. *Scientific Style and Format. The CBE Manual for Authors, Editors, and Publishers*, 6th edn. (Cambridge University Press, Cambridge), ISBN 0-521-47154-0. Day, R., 1995, *Scientific English: A Guide for Scientists and Other Professionals*, 2nd edn. (Oryx, Phoenix, AZ), ISBN 0-89774-898-8. *Chicago Manual of Style: The Essential Guide for Authors, Editors, and Publishers*, 14th edn. (University of Chicago Press, Chicago, IL), ISBN 0-226-10389-7.

2.1. Rapid communications

Reports on exciting new results within the scope of the journal can be submitted for publication in the rapid communications section. A rapid communication should not exceed 700 words and should contain no or only 1 simple table or figure of not more than 8.4 cm = 1 columnwidth. A maximum of 8 references may be used (see section 2.3). The rapid communication should be typewritten, double-spaced and with wide margins. The manuscript should be arranged in the following order: title (not exceeding 100 characters including spaces between words); surname(s) of author(s), preceded by one name spelled out in full: name and address of the establishment where the work was done (all on 1 page); abstract (max. 75 words) and keywords (indexing terms, max. 3 items); text without subheadings; acknowledgement(s); references; figure legend and figure; table. The original and 3 copies should be submitted, accompanied by the disk (see section 1.3). Name, full postal address, telephone, fax numbers and e-mail address of the author to whom correspondence is to be sent should be mentioned on the title page. Rapid communications have priority at the editorial office and publisher.

2.2. Full-length manuscripts and short communications

2.2.1. General

The manuscript of a short communication (which should not exceed 4 pages in print, i.e. approx. 2000-2300 words including abstract, legends and references) and a full-length paper should be arranged as follows.

First page: title (not exceeding 100 characters including spaces between words); surname(s) of author(s), preceded by one name spelled out in full; name and address of the establishment where the work was done; name, full postal address, telephone, fax numbers and e-mail address of the author to whom proofs and other correspondence should be sent. Second page: abstract and keywords (indexing terms, normally 3-6 items). Third page onward, body of the manuscript, divided into the following sections: 1. Introduction; 2. Materials and methods; 3. Results; 4. Discussion; Acknowledgements; References; figure legends and figures; tables (for short communications the total number of tables and figures should not exceed 2). Subdivisions of a section should also be numbered within that section: 2.1., 2.2., 2.3., etc. All pages should be numbered consecutively, the title page being p. 1.

2.2.2. Abstract and keywords

The abstract with keywords should be typed on a separate sheet. The abstract should include: the reason why the experiments were done, a very brief description of the experiments (including species, tissue, etc.), followed by the main results, and finally, a conclusion giving the relevance of the results to the question asked. The abstract must be completely self-explanatory. The abstract should not exceed 150 words (100 words for short communications). No footnotes may be used and a reference, if cited, must be given in full. Standard terms and scientific nomenclature should be used. Abbreviations and contractions,

Notice to Authors ix

except those for weights and measures and those explained, should not be used. Below the abstract, type 3-6 keywords or short phrases suitable for indexing. These terms will be printed at the end of the abstract. If possible, keywords should be selected from *Index Medicus* or *Excerpta Medica Index*. First category keywords (e.g., Hyperphagia; G-Strophantidin; Fibre shortening) will all be listed and cross-indexed. Second category keywords (e.g., Rat, Cold, Metabolite) will only be listed under the index entry for the first category keywords. If the editors feel that keywords should be adjusted to the standards of the journal this will be done without consultation of the author(s).

2.2.3. Introduction, materials and methods, results, discussion

The Introduction should not be an extensive review of the literature but should refer only to previous work which has a direct bearing on the topic to be discussed.

Materials and methods should be written clearly and in such detail that the work can be repeated by others. Procedural detail that has been published previously should be referred to by citation. When a modified procedure is used, only the author's modifications of the previously published method need to be given in detail.

Results should be described concisely. Text, tables and figures must be internally consistent.

The discussion should involve only the relevant findings presented. Wide digressions are unacceptable because of the limitations of space.

2.3. References

Authors are responsible for the accuracy and completeness of their references as these will not be checked by the editorial office.

References should be listed alphabetically (see sample references). Articles written by the same first author with different second authors should be listed according to the first author's surname and then according to the second author's surname. Articles written by the same first author with more than one co-author should be listed alphabetically according to the first author's surname and then according to the year of publication. Two or more references to the same first author with the same publication year should have a, b, c etc. suffixed to the year indicating the alphabetical order of the second or third author, etc.

References to journals should contain the names and initials of the author(s), the year, the full title, the abbreviation of the name of the periodical according to the *List of Serial Title Word Abbreviations* (available from the International Serials Data System, 20 Rue Bachaumont, 75002 Paris, France; ISBN 2-904938-02-8) followed by the volume and page numbers.

References in the text should be cited by the author's name(s) and the year of publication. Examples: De Groat

(1990) or Downie and Larsson (1990) and (De Groat, 1990; Downie and Larsson, 1990; Stoof and Kebabian, 1984). For three or more authors the name of the first author followed by et al. should be used. Examples: Hicks et al. (1988) and (Hicks et al., 1988, 1989; Seeman et al., 1990, 1991a.b.c).

Sample references

Periodicals:

Barnes, P.J., Karin, M., 1997. Nuclear factor-κβ – a pivotal transcription factor in chronic inflammatory diseases. N. Engl. J. Med. 336, 1066-1071.

Paivio, A., Jansen, B., Becker, L.J., 1975. Comparisons through the mind's eye. Cognition 37, 635-647.

Books:

Strunk, W., White, E.B., 1979. The Elements of Style, third ed. MacMillan, New York, NY.

Gurman, A.S., Kniskern, D.P., 1981. Family therapy outcome research: knowns and unknowns. In: Gurman, A.S., Kniskern, D.P. (Eds.), Handbook of Family Therapy. Brunner/Maazel, New York, NY, pp. 742-775.

Order of references:

De Groat, W., 1990.

Maggi, C.A., 1988.

Maggi, C.A., Lecci, A., 1987.

Maggi, C.A., Meli, A., 1986.

Maggi, C.A., Santicoli, P., Meli, A., 1984.

Maggi, C.A., Giuliani, S., Patacchini, R., Rovero, P., Giachetti, A., Meli, A., 1989a.

Maggi, C.A., Patacchini, R., Rovero, P., Giachetti, A., Meli, A., 1989b.Maggi, C.A., Giuliani, S., Patacchini, R., Santicoli, P., Giachetti, A., Meli, A., 1990.

Monsma Jr., F.J., 1989.

Van der Giessen, A., 1990.

The number of references should be kept to a reasonable minimum; to this end, appropriate recent reviews should be cited whenever possible. Unpublished observations, personal communications and manuscripts in preparation or submitted for publication may be referred to in the text but should not appear in the list of references. Manuscripts in press (i.e., accepted for publication) must be included in the references with the name of the journal in which they are to appear.

2.4. Illustrations

Either the original drawings plus 3 good photographs, or 4 good photographs of the drawings (on glossy paper unmounted) or 4 high-quality computer printouts should be submitted. Illustrations may be submitted in electronic format as well, but must always be accompanied by reproducible paper printouts. Photocopies may not be used instead of originals. The photographs should be of adequate definition and contrast. The number of illustrations should be limited to the essential.

(a) It is important to allow for reduction to fit a single column, 8.4 cm wide or at most a double column, maxi-

x Notice to Authors

mally 17.6 cm wide. Illustrations, especially photomicrographs, should preferably be submitted in their final size (single or double column). When possible, all key symbols should be explained in the figures. However, the following symbols can be typeset and explained (as well as all lettering) in the legends: $+ \times \blacksquare \bullet \blacktriangle \lor \multimap \Diamond \triangle$ $\nabla \triangleright \triangleleft \oplus \otimes \odot \ominus \otimes * \bigstar$. All letters and numerals appearing in a particular illustration should be of the same size (approximately 1.4-2 mm height when reduced to 8.4 cm width). Comparable illustrations should carry letters, figures and numerals of the same size when reduced to 8.4 cm width. If the abscissa and the ordinate of a graph require labeling, the label to the abscissa should be placed below the related numerals and the label to the ordinate should be placed horizontally above the ordinate. If this requirement is not complied with, all labels will appear in the legend only.

- (b) Graphs, electrocardiograms and oscillograms should be prepared by a skilled photographer so that the dark, cross-hatched background is eliminated, the faint portions of the graphs are intensified, and a sharp print is obtained. This process may be avoided by using blue-ruled instead of black-ruled recording paper for the originals. Kymograph records on sooted paper should be reversed photographically to ensure tracings are black on a white background.
- (c) Drawings of complicated chemical structures should be prepared in the same way as graphs.
- (d) A calibration bar should be drawn on the micrographs instead of giving a magnification factor in the figure legend.
- (e) All illustrations should be referred to as figures and numbered in Arabic numerals (Fig. 1, 2, etc.).
- (f) Legends to figures should make these comprehensible without reference to the text.
- (g) Colour reproduction of illustrations is available at cost. Original high-quality illustrations (preferably slides) should be well protected against possible damage during shipment. Detailed information regarding the use of colour may be obtained from the publisher at the time of submission of the manuscript to the editors.

2.5. Tables

Tables should be prepared for use in a single column (8.4 cm wide) or be of page width (17.6 cm).

- (a) Each table should have a brief explanatory heading and sufficient experimental detail (following the table body as a footnote) so as to be intelligible without reference to the text.
- (b) Tables should not duplicate material in text or illustrations.
- (c) Short or abbreviated column headings should be used and, if necessary, explained in footnotes, and indicated as ^a, ^b, ^c, etc.

- (d) Statistical measures of variation, S.D., S.E., etc. should be identified.
- (e) Tables should be numbered separately in Arabic numerals (Table 1, 2, etc.).

2.6. Formulas and equations

Structural chemical formulas, process flow diagrams and complicated mathematical expressions should be clear. All subscripts, superscripts, Greek letters and unusual characters must be identified. Structural chemical formulas and process flow diagrams should be prepared in the same way as graphs.

3. Correcting proofs

One set of proofs will be sent to the corresponding author. To ensure speedy correction of galley proofs, it is essential to have on the title page of the manuscript the name and full postal address (plus telephone, fax numbers and e-mail address) of the author to whom the proofs should be sent. Proofs will usually be of lower quality paper. These proofs are automatically produced, low-resolution laser-printer outputs. The final product will naturally meet our high-quality standards regarding resolution and page lay-out. Please use these proofs solely for checking of typesetting/editing and completeness of text and figures. Only printer's errors may be corrected; no changes in, or additions to, the edited manuscript will be allowed. If your proofs contain an "Unlinked References" section, then the references listed in it are not cited in your article. Please cite them where appropriate or delete them from the "References" list. Proofs should be returned within 48 hours to Elsevier Science B.V., P.O. Box 1527, 1000 BM Amsterdam, The Netherlands, preferably by fax ((31-20) 485-3239). If this time is exceeded no reminder will be sent, the manuscript will be read by the editorial staff of the publisher only and printed without the author's corrections.

4. Page charges and reprints

There will be no page charge. Authors of a full-length paper will receive a reprint order form which must be completed and returned to the publisher with the proofs. Authors of short communications and rapid communications will receive a reprint order form; this order form should be completed and mailed to the publisher by return post. Reprints ordered after the journal has been printed will cost considerably more than those ordered immediately.